[1]汪汉,刘汉雄,蔡琳.2019冠状病毒病的心血管表现[J].心血管病学进展,2020,(11):1152-1155.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
　WANG Han,LIU Hanxiong,CAI Lin.Cardiovascular Profiles in Corona V irus Disease 2019[J].Advances in Cardiovascular Diseases,2020,(11):1152-1155.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
点击复制

2019冠状病毒病的心血管表现()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年11期
页码:
1152-1155
栏目:
综述
出版日期:
2020-11-25

文章信息/Info

Title:
Cardiovascular Profiles in Corona V irus Disease 2019
文章编号:
202004089
作者:
汪汉；刘汉雄；蔡琳
(西南交通大学附属医院 成都市第三人民医院心内科,四川 成都 610031)
Author(s):
WANG Han;  LIU Hanxiong;  CAI Lin
(Department of Cardiology, The Third Peoples Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu 610031, Sichuan, China)
关键词:
新型冠状病毒; 2019冠状病毒病; 心肌损伤; 免疫; 炎症
Keywords:
Novel coronavirus;  Corona virus disease 2019 ;  Myocardial injury;  Immunity;  Inflammation
DOI:
10.16806/j.cnki.issn.1004-3934.2020.11.000
摘要:
目前，2019新型冠状病毒已扩散至全球100多个国家，感染人数为160余万，死亡率高，对人类生命安全造成严重威胁。除累及呼吸系统造成呼吸衰竭外，与病毒感染相关的心肌损伤也逐渐受到重视。现将其与严重急性呼吸综合征比较，阐释新型冠状病毒疾病相关心肌损伤的发病机制、病理学改变、高危人群、临床表现、诊断、治疗以及预后。
Abstract:
2019 novel coronavirus has spread to more than 100 countries around the world. The number of people infected has reached more than 1.6 million, and the mortality rate is high, which poses a serious threat to human life and safety. In addition to respiratory diseases, myocardial injury related to virus infection has been paid more and more attention. In this paper, we compared it with SARS to explain the pathogenesis, pathological changes, high-risk population, clinical manifestation, diagnosis, treatment and prognosis of novel coronavirus disease-related myocardial injury

参考文献/References:

[1] Huang C,Wang Y,Li X,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China [J]. Lancet,2020,395(10223):497-506.

[2] Huang X,Wei F,Hu L,et al. Epidemiology and clinical characteristics of COVID-19[J]. Arch Iran Med March ,2020,23(4):268-271.

[3] Peiris JS,Yuen KY,Osterhaus AD,et al. The severe acute respiratory syndrome[J]. N Engl J Med,2003,349(25):2431-2441.

[4] Zhou P,Yang XL,Wang XG,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature,2020,579(7798):270-273.

[5] Wrapp D,Wang N,Corbett KS,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science,2020,367(6483):1260-1263.

[6] Wang D,Hu B,Hu C,et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J]. JAMA,2020,323(11):1061-1069.

[7] Guan W,Ni Z,Hu Y,et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Eng J Med,2020,382(18):1708-1720.

[8] 郎振为,张立洁,张世杰,等. 严重急性呼吸综合征3例尸检病理分析[J].中华病理学杂志,2003,32(3):201-204.

[9] Xu Z,Shi L,Wang Y,et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med,2020,8(4):420-422.

[10] 陈倩,王瑶,焦方舟,等. 新型冠状病毒肺炎炎症风暴的发生机制及干预策略[J]. 中华传染病杂志, 2020,38(3):185-188 .

[11] Zhang Y,Xiao M,Zhang S,et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19[J]. N Engl J Med,2020,382(17):e38.

[12] 刘彤华. 从SARS病理得到的启示[J]. 中华病理学杂志, 2003,32(3):193-194.

[13] 丁彦青,王慧君,申洪,等. 严重急性呼吸综合征病原体检测及临床病理学观察[J]. 中华病理学杂志,2003,32(3):195-200.

[14] 国家卫生与健康委员会. 《新型冠状病毒肺炎诊疗方案》（试行第七版）[M]. 2020.

[15] Cai G. Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2,the receptor of 2019-nCoV[J].补充杂志名？？ https://www.medrxiv.org/content/10.1101/2020.02.05.20020107v2.full.

[16] Jia X,Yin C,Lu S,et al. Two things about COVID-19 might need attention[J]. Preprints,2020,2020020315.DOI:10.20944/preprints202002.0315.v1.

[17] 高润霖.严重急性呼吸综合征与心脏[J]. 中华心血管病杂志, 2003,31(10):721-722.

[18] Shi S,Qin M,Shen B,et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan,China[J]. JAMA Cardiol,2020,5(7):802-810.

[19] 黄鹤,吴钢,赵庆彦,等. 新性冠状病毒肺炎合并心律失常的诊疗建议[J]. 中华心律失常学杂志,2020,DOI:10.3760/cma.j.cn.113859-20200304-00052.

[20] Li B,Yang J,Zhao F,et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China[J]. Clin Res Cardiol,2020,109(5):531-538.

[21] Driggin E,Madhavan MV,Bikdeli B,et al. Cardiovascular considerations for patients,health care Workers,and health systems during the coronavirus disease 2019(COVID-19) pandemic[J]. J Am Coll Cardiol,2020,75(18):2352-2371.

[22] 赵妍,王文尧,田间,等. 成人急性病毒性心肌炎的临床表现与相关因素分析[J]. 中国循环杂志,2019,34(6):592-596.

[23] Russell CD,Millar JE,Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury[J]. Lancet,2020, 395(10223):473-475.

[24] Zhao JP,Hu Y,Du RH,et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia[J]. Zhonghua Jie He He Hu Xi Za Zhi,2020,43(3):183-184.

[25] Chen N,Zhou M,Dong X,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J]. Lancet,2020,395(10223):507-513.

相似文献/References:

[1]谭斯露 何胜虎.新型冠状病毒与SARS病毒的相似性及对心脏的影响[J].心血管病学进展,2020,(9):947.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.015]
　TAN Silu,HE Shenghu.Similarity of Novel Coronavirus and SARS Virus and Their Effects on Heart[J].Advances in Cardiovascular Diseases,2020,(11):947.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.015]
[2]张艺文 蔡琳 秦莉 杨晓倩 汪汉.基于网络药理学的参麦注射液治疗新型冠状病毒感染合并心肌炎的机制研究[J].心血管病学进展,2020,(10):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
　ZHANG YiwenCAI LinQIN LiYANG XiaoqianWANG Han.Shenmai Injection for COVID-19 with Myocarditis Based on Network Pharmacology[J].Advances in Cardiovascular Diseases,2020,(11):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
[3]杨晓倩 秦莉 张艺文 汪汉.苦参治疗新型冠状病毒感染合并心肌炎的网络药理学分析[J].心血管病学进展,2021,(6):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
　YANG Xiaoqian,QIN Li,ZHANG Yiwen,et al.Network Pharmacological Analysis of Sophora Flavescens on Novel Coronavirus Infection complicated with Myocarditis[J].Advances in Cardiovascular Diseases,2021,(11):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]

更新日期/Last Update: 2021-02-03